Regression of endometrial autografts in a rat model of endometriosis treated with etanercept

Islimye, Mine; Kılıç, Sevtap; Zülfikaroğlu, Ebru; Topcu, Onur; Zergeroğlu, Sema; Batıoğlu, Sertaç

doi:10.1016/j.ejogrb.2011.06.029

Cited by 34 publications

(30 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, new therapeutic agents that do not affect fertility and are as effective as hormone therapies have been investigated at recent studies with regard to the treatment of endometriosis [23-25]. These studies have shown that etanercept reduces implant volume and histopathological scores with no effect on fertility, and infliximab (a monoclonal antibody against TNF-α) also has the same effect [17, 24]; however, Shakiba and Falcone [26] in their case report did not show any benefit of etanercept in a human model with an advanced stage of endometriosis. In the Cochrane review about the treatment of anti-TNF-α for pelvic pain-associated endometriosis, there was no benefit of infliximab for pelvic pain-associated endometriosis and endometriotic lesions [27].…”

Section: Discussionmentioning

confidence: 99%

“…Etanercept, which is combined with soluble TNF receptor 2 with the Fc portion of human immunoglobulin G1 antibody, is produced by recombinant DNA technologies [16]. In previous animal model studies, etanercept reduced the size of endometrial implants and improved prognosis of disease [17]. Therefore, etanercept has been suggested as a new-generation therapy for endometriosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Etanercept on the Success of Assisted Reproductive Technology in Patients with Endometrioma

Önalan

Tohma

Zeyneloğlu³

2017

Gynecol Obstet Invest

View full text Add to dashboard Cite

Aims: To determine the effects of a tumor necrosis factor inhibitor (etanercept) on pregnancy outcomes in patients with endometrioma who were treated with assisted reproductive technology. Methods: Sixty-eight infertile patients who had endometrioma were included in our retrospective case-control study. We administered etanercept (Enbrel, 50 mg in 1 mL intramuscularly) to 19 patients on the second day of their previous menstrual cycle. All patients were treated with assisted reproductive technology. Pregnancy and live birth rates (LBR) were documented. Results: When all other parameters (age, body mass index, infertility) are supposed to be constant, the clinical pregnancy rate was significantly higher in patients who used etanercept in an antagonist protocol than in patients who did not use etanercept (χ² = 5.547; p = 0.019) but LBR did not reach a statistical significance (χ² = 3.179; p = 0.075). The use of etanercept had an OR of 4.17 (95% CI 1.23–14.14) compared with not using etanercept for clinical pregnancy rate. The use of etanercept increased the rate of pregnancy (χ² = 6.55; p = 0.01). The pregnancy rate with the use of etanercept had an OR of 4.23 (95% CI 1.35–13.25) compared with patients who did not use etanercept. In the same way, the use of etanercept increased LBR twofold, but it is not significant in the border line (χ² = 3.771; p = 0.052). Conclusions: Etanercept may be a new non-hormonal therapy that may be an adjunct to treatment of infertile women with endometrioma. However, the safety of etanercept on embryos and fetuses has not been fully clarified.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effect of Etanercept on the Success of Assisted Reproductive Technology in Patients with Endometrioma

Önalan

Tohma

Zeyneloğlu³

2017

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…The effects of etanercept on endometriotic implants in a rat model were evaluated in randomized controlled studies (14)(15)(16)(17). Treated animals showed significant changes in the volume of lesions, histopathologic scores, and molecular parameters such as serum levels of VEGF, IL-6, and TNF-a.…”

Section: Pharmacologic Groups Tested In In Vitro/animal Models Of Endmentioning

confidence: 99%

Pharmacologic therapies in endometriosis: a systematic review

Soares¹,

Martínez-Varea

Hidalgo-Mora

et al. 2012

Fertility and Sterility

138

View full text Add to dashboard Cite

“…In a refinement of the autotransplant model, MRI was used to serially and noninvasively monitor lesion growth and to obtain lesion volumes allowing for a reduction in animal usage . Subsequently, the rat model has been used in many studies as a test‐bed for potential therapeutics including melatonin , doxycycline , Etanercept (tumor necrosis factor α antibody) , and gene therapy delivered via polymeric micelles . The natural, mixed dopamine receptor antagonist Levo‐tetrahydropalmatine (L‐THP) was shown to reduce lesion growth and to alleviate generalized hyperalgesia .…”

Section: In Vitro and In Vivo Model Systemsmentioning

confidence: 99%

Relevant human tissue resources and laboratory models for use in endometriosis research

Greaves

Critchley

Horne

et al. 2017

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Endometriosis is characterized by the growth of endometrium‐like tissue outside the uterus, most commonly on the pelvic peritoneum and ovaries. Although it may be asymptomatic in some women, in others it can cause debilitating pain, infertility or other symptoms including fatigue. Current research is directed both at understanding the complex etiology and pathophysiology of the disorder and at the development of new nonsurgical approaches to therapy that lack the unwanted side effects of current medical management. Tools for endometriosis research fall into two broad categories; patient‐derived tissues, and fluids (and cells isolated from these sources) or models based on the use of cells or animals. In this review, we discuss the literature that has reported data from the use of these tools in endometriosis research and we highlight the strengths and weaknesses of each. Although many different models are reported in the literature, hypothesis‐driven research will only be facilitated with careful experimental design and selection of the most appropriate human tissue from patients with and without endometriosis and combinations of physiologically relevant in vitro and in vivo laboratory models.

show abstract

Regression of endometrial autografts in a rat model of endometriosis treated with etanercept

Cited by 34 publications

References 24 publications

Effect of Etanercept on the Success of Assisted Reproductive Technology in Patients with Endometrioma

Effect of Etanercept on the Success of Assisted Reproductive Technology in Patients with Endometrioma

Pharmacologic therapies in endometriosis: a systematic review

Relevant human tissue resources and laboratory models for use in endometriosis research

Contact Info

Product

Resources

About